Aldosterone Antagonists Reduce the Risk of Cardiovascular Mortality in Dialysis Patients: A Meta-Analysis

Table 1

Characteristics of all qualified studies included in the meta-analysis.

Study	Country	patients	N. of P.	Treatment	Drug control	Follow-up	Outcomes
Shahram Taheri (2009)	Iran	HD	16	Spironolactone 25mg three times a week	placebo	6 months	LVMI, LVEF, adverse events
Shahram Taheri (2012)	Iran	PD	18	Spironolactone 25mg every other day	placebo	6 months	LVEF, CCV mortality, all-cause mortality, adverse events
Inna Zaripova (2012)	Russian	HD	71	Spironolactone 25mg once daily	N/A	6 months	LVMI
Yoshihiro Matsumoto (2013)	Japan	HD	309	Spironolactone 25mg once daily	N/A	36 months	CCV mortality, all-casuse mortality, adverse events
Yasuhiko Ito (2014)	Japan	PD	158	Spironolactone 25mg once daily	N/A	24 months	LVMI, LVEF, all-cause mortality, adverse events
Greicy Mara (2015)	Brazil	HD	17	Spironolactone 12.5mg or 25mg once daily	placebo	6 months	LVMI, LVEF, SBP, DBP, aldosterone, adverse enents
Michael Walsh (2015)	Canada	HD	154	Eplerenone 50mg once daily	placebo	3months	CCV mortality, all-cause mortality, adverse events
ChongTing Lin (2015)	China	HD+PD	253	Spironolactone 25mg once daily	placebo	24 months	LVMI, CCV mortality, all-cause mortality, aldosterone, adverse events
XiaoLi Song (2017)	China	HD	80	Spironolactone 5mg once daily	placebo	12 months	LVEF
ChaoChao Wang (2018)	China	PD	96	Spironolactone 20mg once daily+ACEI/ARB	ACEI/ARB	12months	LVEF, LVMI

N. of P.: the number of patients; HD: hemodialysis; PD: peritoneal dialysis; N/A: no treatment.